Invitrogen™ BCL6 Monoclonal Antibody (BCL-UP), PerCP-eFluor™ 710, eBioscience™

Beschreibung

Description: The monoclonal antibody BCL-UP recognizes Bcl-6, also known as B-cell lymphoma 6,which is a member of the POZ family of transcriptional repressors. Bcl-6 is expressed most abundantly in germinal center B cells, as well as in differentiating and activated B cells. This 79 kDa protein is essential for germinal center B cell proliferation and survival. During B cell development, Bcl-6 plays an important role in promoting pre-B cell survival to enable the generation of a diverse B cell repertoire. Moreover, Bcl-6 is expressed constitutively in diffuse large B cell lymphomas (DLBCLs), Burkitt's lymphoma, and non-Hodgkin's lymphoma. Reports also suggest expression of Bcl-6 in CD4+ T follicular helper cells and memory T cells. Bcl-6 has been reported to be antagonized by Blimp-1. Applications Reported: This BCL-UP antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This BCL-UP antibody has been pre-titrated and tested by intracellular flow cytometric analysis of human tonsil cells using the Foxp3 Fixation/Permeabilization Buffers (Product # 00-5521-00) and protocol. Please see BestProtocols® Section (Staining intracellular Antigens for Flow Cytometry) for staining protocol (refer to Protocol B: One-step protocol for intracellular (nuclear) proteins). This can be used at 5 μL (0.03 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volu...

Bcl-6 proto-oncogene product (a Kruppel-type zinc-finger protein) is mainly expressed in normal germinal center B cells and related lymphomas. Bcl-6 is involved in chromosome rearrangements at 3q27 in non-Hodgkin's lymphomas and Bcl-6 rearrangements have been detected in 33%-45% of diffuse large B cell lymphomas. Bcl-6 has been detected immunohistochemically in follicular lymphomas, diffuse large B cell lymphomas, Burkitt's lymphomas and in nodular, lymphocyte predominant Hodgkin's disease.